(AXSM) Axsome Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 12.010m USD | Total Return: 112.1% in 12m
Avg Turnover: 140M
Qual. Beats: -1
Rev. Trend: 99.4%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -34.1 is critical
Altman Z'' -6.45 < 1.0 - financial distress zone
Tailwinds
Supp Ema20, Rs Leader, Idiosyncratic Leader
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Its current commercial portfolio includes Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. The company operates within the high-barrier CNS sector, where drug development often requires navigating complex regulatory pathways and multi-mechanistic pharmacological profiles.
The company maintains an extensive clinical pipeline, including AXS-07 for acute migraine treatment and several late-stage candidates. Notable investigational assets include AXS-05 for Alzheimer’s disease agitation and smoking cessation, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Most biopharmaceutical firms in this stage utilize a research-heavy business model, frequently partnering with academic institutions like Duke University to validate therapeutic efficacy through multi-phase clinical trials.
Investors may find additional data points on these clinical developments by exploring the resources at ValueRay. Based in New York, Axsome continues to transition from a development-stage entity to a fully integrated commercial organization by expanding the indications for its existing molecular compounds.
- Auvelity prescription growth and market share expansion drive primary revenue growth
- Sunosi label expansion into ADHD and binge eating disorders increases addressable market
- FDA approval decisions for AXS-07 and AXS-14 create significant regulatory catalysts
- Phase 3 clinical trial readouts for Alzheimer’s disease agitation influence valuation
- Commercial scaling costs and R&D spending impact path to sustained profitability
| Net Income: -188.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 9.93 > 1.0 |
| NWC/Revenue: 24.28% < 20% (prev 58.02%; Δ -33.73% < -1%) |
| CFO/TA -0.10 > 3% & CFO -70.7m > Net Income -188.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.2m) vs 12m ago 4.76% < -2% |
| Gross Margin: 92.60% > 18% (prev 91.49%; Δ 1.11% > 0.5%) |
| Asset Turnover: 108.1% > 50% (prev 72.43%; Δ 35.68% > 0%) |
| Interest Coverage Ratio: -34.13 > 6 (EBIT TTM -181.2m / Interest Expense TTM 5.31m) |
| A: 0.24 (Total Current Assets 611.2m - Total Current Liabilities 439.2m) / Total Assets 713.6m |
| B: -1.92 (Retained Earnings -1.37b / Total Assets 713.6m) |
| C: -0.28 (EBIT TTM -181.2m / Avg Total Assets 655.1m) |
| D: 0.08 (Book Value of Equity 54.6m / Total Liabilities 659.0m) |
| Altman-Z'' = -6.45 = D |
| DSRI: 0.95 (Receivables 251.1m/161.4m, Revenue 708.2m/432.2m) |
| GMI: 0.99 (GM 91.49% / 92.60%) |
| AQI: 0.88 (AQ_t 0.12 / AQ_t-1 0.13) |
| SGI: 1.64 (Revenue 708.2m / 432.2m) |
| TATA: -0.16 (NI -188.3m - CFO -70.7m) / TA 713.6m) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of June 04, 2026, the stock is trading at USD 233.49 with a total of 774,516 shares traded.
Over the past week, the price has changed by -0.44%,
over one month by +4.38%,
over three months by +42.33% and
over the past year by +112.05%.
Axsome Therapeutics has received a consensus analysts rating of 4.74. Therefore, it is recommended to buy AXSM.
- StrongBuy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 270.3 | 15.8% |
P/E Forward = 333.3333
P/S = 16.9579
P/B = 221.0846
Revenue TTM = 708.2m USD
EBIT TTM = -181.2m USD
EBITDA TTM = -172.7m USD
Long Term Debt = 117.8m USD (from longTermDebt, last quarter)
Short Term Debt = 70.6m USD (from shortTermDebt, last quarter)
Debt = 248.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 32.0m
Net Debt = -56.3m USD (calculated: Debt 248.8m - CCE 305.1m)
Enterprise Value = 12.0b USD (12.0b + Debt 248.8m - CCE 305.1m)
Interest Coverage Ratio = -34.13 (Ebit TTM -181.2m / Interest Expense TTM 5.31m)
EV/FCF = -168.4x (Enterprise Value 12.0b / FCF TTM -71.0m)
FCF Yield = -0.59% (FCF TTM -71.0m / Enterprise Value 12.0b)
FCF Margin = -10.02% (FCF TTM -71.0m / Revenue TTM 708.2m)
Net Margin = -26.59% (Net Income TTM -188.3m / Revenue TTM 708.2m)
Gross Margin = 92.60% ((Revenue TTM 708.2m - Cost of Revenue TTM 52.4m) / Revenue TTM)
Gross Margin QoQ = 92.30% (prev 93.71%)
Tobins Q-Ratio = 16.75 (Enterprise Value 12.0b / Total Assets 713.6m)
Interest Expense / Debt = 2.14% (Interest Expense 5.31m / Debt 248.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -143.2m (EBIT -181.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.39 (Total Current Assets 611.2m / Total Current Liabilities 439.2m)
Debt / Equity = 4.56 (Debt 248.8m / totalStockholderEquity, last quarter 54.6m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -56.3m / EBITDA -172.7m)
Debt / FCF = 0.79 (negative FCF - burning cash) (Net Debt -56.3m / FCF TTM -71.0m)
Total Stockholder Equity = 72.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.74% (Net Income -188.3m / Total Assets 713.6m)
RoE = -260.0% (Net Income TTM -188.3m / Total Stockholder Equity 72.4m)
RoCE = -95.25% (EBIT -181.2m / Capital Employed (Equity 72.4m + L.T.Debt 117.8m))
RoIC = -46.24% (negative operating profit) (NOPAT -143.2m / Invested Capital 309.6m)
WACC = 7.31% (E(12.0b)/V(12.3b) * Re(7.43%) + D(248.8m)/V(12.3b) * Rd(2.14%) * (1-Tc(0.21)))
Discount Rate = 7.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 3.55%
[DCF] Fair Price = unknown (Cash Flow -71.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.55 | # QB: -1
Revenue Correlation: 99.36 | Revenue CAGR: 61.29% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.82 | Chg30d=-47.48% | Revisions=-25% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.34 | Chg30d=-471.67% | Revisions=-50% | Analysts=8
EPS current Year (2026-12-31): EPS=-1.71 | Chg30d=-63.73% | Revisions=-40% | GrowthEPS=+50.9% | GrowthRev=+54.4%
EPS next Year (2027-12-31): EPS=5.89 | Chg30d=-3.21% | Revisions=+11% | GrowthEPS=+445.1% | GrowthRev=+61.7%
[Analyst] Revisions Ratio: -50%